Acute coronary syndromes

anticoagulation, take into account all of the following when thinking about the duration and type (dual or single) of antiplatelet therapy in the 12 months after an acute coronary syndrome: • bleeding risk • thromboembolic risk • cardiovascular risk • person's wishes. Be aware that the optimal duration of aspirin therapy has not been established, and that long-term continuation of aspirin, clopidogrel and oral anticoagulation (triple therapy) significantly increases bleeding risk. [2020] 1.4.22 For people already on anticoagulation who have had PCI, continue anticoagulation and clopidogrel for up to 12 months. If the person is taking a direct oral anticoagulant, adjust the dose according to bleeding risk, thromboembolic risk and cardiovascular risk. [2020] 1.4.23 For people with a new indication for anticoagulation who have had PCI, offer clopidogrel (to replace prasugrel or ticagrelor) for up to 12 months and an oral anticoagulant licensed for the indication, which best matches the person's: Acute coronary syndromes (NG185) • bleeding risk • thromboembolic risk • cardiovascular risk • wishes. [2020] 1.4.24 For people already on anticoagulation, or those with a new indication, who have not had PCI (medical management, CABG), continue anticoagulation and, unless there is a high risk of bleeding, consider continuing
